FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009964061> ?p ?o ?g. }

• W3009964061 endingPage "e516" @default.
• W3009964061 startingPage "e510" @default.
• W3009964061 abstract "BackgroundThis prospective study collected quality of life (QoL) and pain data during cabazitaxel treatment in patients with advanced metastatic or castration-resistant prostate cancer (mCRPC).Patients and MethodsFunctional Assessment of Cancer Therapy-Prostate (QoL) and Brief Pain Inventory-Short Form (pain) questionnaires were collected over 6 months.ResultsIn 61 patients with mCRPC (median age, 72 years) from 22 centers, metastatic sites were bones (97%), lymph nodes (36%), and visceral (20%); 25% received cabazitaxel in the second line, 29% in the third line, and 46% in the fourth line or beyond. All had been previously treated with docetaxel, except one with paclitaxel, and 75% also with abiraterone, enzalutamide, or both. The median cabazitaxel duration was 3.4 months. Forty-nine patients were evaluable for QoL and 44 for pain. QoL was improved in 37%, maintained in 35%, and deteriorated in 37%. In 27%, pain decreased ≥ 1 level and remained stable in 52%. A total of 34% lowered analgesic drug level. Prostate-specific antigen response ≥ 50% was observed in 11 (32.6%) patients, of whom 7 improved QoL and 1 was stable. At 6 months, 83.6% survived (95% confidence interval, 71.7%-90.8%). A total of 46% had ≥ 1 grade ≥ 3 adverse events, mainly anemia and neutropenia.ConclusionAlthough cabazitaxel was given as the third line and beyond for three-quarters of patients, over one-third had improved QoL and/or decreased pain during treatment." @default.
• W3009964061 created "2020-03-13" @default.
• W3009964061 creator A5007779528 @default.
• W3009964061 creator A5012421372 @default.
• W3009964061 creator A5020558306 @default.
• W3009964061 creator A5022866198 @default.
• W3009964061 creator A5024478673 @default.
• W3009964061 creator A5037790116 @default.
• W3009964061 creator A5042461515 @default.
• W3009964061 creator A5043674220 @default.
• W3009964061 creator A5047019507 @default.
• W3009964061 creator A5052636813 @default.
• W3009964061 creator A5067979246 @default.
• W3009964061 creator A5070487088 @default.
• W3009964061 creator A5084075491 @default.
• W3009964061 date "2020-10-01" @default.
• W3009964061 modified "2023-10-09" @default.
• W3009964061 title "Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice" @default.
• W3009964061 cites W1964687939 @default.
• W3009964061 cites W2004361934 @default.
• W3009964061 cites W2004909463 @default.
• W3009964061 cites W2015336715 @default.
• W3009964061 cites W2029087193 @default.
• W3009964061 cites W2054346664 @default.
• W3009964061 cites W2108679313 @default.
• W3009964061 cites W2120292596 @default.
• W3009964061 cites W2123526148 @default.
• W3009964061 cites W2131952914 @default.
• W3009964061 cites W2135363794 @default.
• W3009964061 cites W2139248078 @default.
• W3009964061 cites W2740979023 @default.
• W3009964061 cites W2748586176 @default.
• W3009964061 cites W2789265292 @default.
• W3009964061 cites W2800410357 @default.
• W3009964061 cites W2885183647 @default.
• W3009964061 cites W2977469640 @default.
• W3009964061 cites W2988634870 @default.
• W3009964061 doi "https://doi.org/10.1016/j.clgc.2020.02.003" @default.
• W3009964061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32229267" @default.
• W3009964061 hasPublicationYear "2020" @default.
• W3009964061 type Work @default.
• W3009964061 sameAs 3009964061 @default.
• W3009964061 citedByCount "10" @default.
• W3009964061 countsByYear W30099640612020 @default.
• W3009964061 countsByYear W30099640612021 @default.
• W3009964061 countsByYear W30099640612022 @default.
• W3009964061 countsByYear W30099640612023 @default.
• W3009964061 crossrefType "journal-article" @default.
• W3009964061 hasAuthorship W3009964061A5007779528 @default.
• W3009964061 hasAuthorship W3009964061A5012421372 @default.
• W3009964061 hasAuthorship W3009964061A5020558306 @default.
• W3009964061 hasAuthorship W3009964061A5022866198 @default.
• W3009964061 hasAuthorship W3009964061A5024478673 @default.
• W3009964061 hasAuthorship W3009964061A5037790116 @default.
• W3009964061 hasAuthorship W3009964061A5042461515 @default.
• W3009964061 hasAuthorship W3009964061A5043674220 @default.
• W3009964061 hasAuthorship W3009964061A5047019507 @default.
• W3009964061 hasAuthorship W3009964061A5052636813 @default.
• W3009964061 hasAuthorship W3009964061A5067979246 @default.
• W3009964061 hasAuthorship W3009964061A5070487088 @default.
• W3009964061 hasAuthorship W3009964061A5084075491 @default.
• W3009964061 hasBestOaLocation W30099640611 @default.
• W3009964061 hasConcept C121608353 @default.
• W3009964061 hasConcept C126322002 @default.
• W3009964061 hasConcept C143998085 @default.
• W3009964061 hasConcept C159110408 @default.
• W3009964061 hasConcept C197934379 @default.
• W3009964061 hasConcept C2776551883 @default.
• W3009964061 hasConcept C2777511904 @default.
• W3009964061 hasConcept C2777899217 @default.
• W3009964061 hasConcept C2778971682 @default.
• W3009964061 hasConcept C2779951463 @default.
• W3009964061 hasConcept C2780192828 @default.
• W3009964061 hasConcept C2781190966 @default.
• W3009964061 hasConcept C530470458 @default.
• W3009964061 hasConcept C61367390 @default.
• W3009964061 hasConcept C71924100 @default.
• W3009964061 hasConceptScore W3009964061C121608353 @default.
• W3009964061 hasConceptScore W3009964061C126322002 @default.
• W3009964061 hasConceptScore W3009964061C143998085 @default.
• W3009964061 hasConceptScore W3009964061C159110408 @default.
• W3009964061 hasConceptScore W3009964061C197934379 @default.
• W3009964061 hasConceptScore W3009964061C2776551883 @default.
• W3009964061 hasConceptScore W3009964061C2777511904 @default.
• W3009964061 hasConceptScore W3009964061C2777899217 @default.
• W3009964061 hasConceptScore W3009964061C2778971682 @default.
• W3009964061 hasConceptScore W3009964061C2779951463 @default.
• W3009964061 hasConceptScore W3009964061C2780192828 @default.
• W3009964061 hasConceptScore W3009964061C2781190966 @default.
• W3009964061 hasConceptScore W3009964061C530470458 @default.
• W3009964061 hasConceptScore W3009964061C61367390 @default.
• W3009964061 hasConceptScore W3009964061C71924100 @default.
• W3009964061 hasFunder F4320307115 @default.
• W3009964061 hasFunder F4320307765 @default.
• W3009964061 hasFunder F4320307769 @default.
• W3009964061 hasFunder F4320307770 @default.
• W3009964061 hasFunder F4320307771 @default.
• W3009964061 hasFunder F4320307778 @default.

• next